Nothing Special   »   [go: up one dir, main page]

BRPI1015568B8 - derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica - Google Patents

derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica

Info

Publication number
BRPI1015568B8
BRPI1015568B8 BRPI1015568A BRPI1015568A BRPI1015568B8 BR PI1015568 B8 BRPI1015568 B8 BR PI1015568B8 BR PI1015568 A BRPI1015568 A BR PI1015568A BR PI1015568 A BRPI1015568 A BR PI1015568A BR PI1015568 B8 BRPI1015568 B8 BR PI1015568B8
Authority
BR
Brazil
Prior art keywords
derivatives
inhibitors
pharmaceutical composition
cyp
disubstituted imidazolidin
Prior art date
Application number
BRPI1015568A
Other languages
English (en)
Inventor
Gaul Christoph
G Bock Mark
Sengupta Saumitra
Rao Gummadi Venkateshwar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42357251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015568(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI1015568A2 publication Critical patent/BRPI1015568A2/pt
Publication of BRPI1015568B1 publication Critical patent/BRPI1015568B1/pt
Publication of BRPI1015568B8 publication Critical patent/BRPI1015568B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

derivados de imidazolidin-2-ona 1,3-dis-substituídos, composição farmacêutica, seus usos, bem como combinação compreendendo os referidos derivados. a presente invenção se refere a compostos de fórmulas (i) e (i-i), ou um sal farmaceuticamente aceitável do mesmo, onde r53, r54, p, q e n são conforme aqui definido. os compostos da presente invenção foram constatados ser úteis como inibidores de 17(alfa)-hidroxilase/c17, 20-liase.
BRPI1015568A 2009-06-26 2010-06-24 derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica BRPI1015568B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1500/CHE/2009 2009-06-26
IN1500CH2009 2009-06-26
IN2181/DEL/2009 2009-10-21
IN2181DE2009 2009-10-21
PCT/EP2010/059029 WO2010149755A1 (en) 2009-06-26 2010-06-24 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17

Publications (3)

Publication Number Publication Date
BRPI1015568A2 BRPI1015568A2 (pt) 2016-08-16
BRPI1015568B1 BRPI1015568B1 (pt) 2020-11-17
BRPI1015568B8 true BRPI1015568B8 (pt) 2021-05-25

Family

ID=42357251

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015568A BRPI1015568B8 (pt) 2009-06-26 2010-06-24 derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica

Country Status (44)

Country Link
US (3) US8263635B2 (pt)
EP (1) EP2445903B1 (pt)
JP (1) JP5456891B2 (pt)
KR (1) KR101360725B1 (pt)
CN (1) CN102803250B (pt)
AR (1) AR078228A1 (pt)
AU (1) AU2010264698C1 (pt)
BR (1) BRPI1015568B8 (pt)
CA (1) CA2765983C (pt)
CL (1) CL2011003266A1 (pt)
CO (1) CO6480927A2 (pt)
CR (1) CR20110684A (pt)
CU (1) CU24039B1 (pt)
CY (1) CY1115426T1 (pt)
DK (1) DK2445903T3 (pt)
DO (1) DOP2011000399A (pt)
EA (1) EA021011B1 (pt)
EC (1) ECSP12011625A (pt)
ES (1) ES2475945T3 (pt)
GE (1) GEP20156250B (pt)
HK (1) HK1164876A1 (pt)
HN (1) HN2011003371A (pt)
HR (1) HRP20140593T1 (pt)
IL (1) IL216741A (pt)
JO (1) JO2892B1 (pt)
MA (1) MA33451B1 (pt)
ME (1) ME01886B (pt)
MX (1) MX2011013771A (pt)
MY (1) MY155570A (pt)
NI (1) NI201100223A (pt)
NZ (1) NZ596488A (pt)
PE (1) PE20121048A1 (pt)
PL (1) PL2445903T3 (pt)
PT (1) PT2445903E (pt)
RS (1) RS53384B (pt)
SG (1) SG176105A1 (pt)
SI (1) SI2445903T1 (pt)
SM (1) SMT201400091B (pt)
TN (1) TN2011000611A1 (pt)
TW (1) TWI492942B (pt)
UA (1) UA105794C2 (pt)
UY (1) UY32730A (pt)
WO (1) WO2010149755A1 (pt)
ZA (1) ZA201108373B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2445502T (lt) 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
AU2011285724B2 (en) 2010-08-04 2015-01-22 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
JP2013537210A (ja) * 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
KR20140053836A (ko) 2011-01-11 2014-05-08 글락소스미스클라인 엘엘씨 조합물
JP6002210B2 (ja) 2011-04-28 2016-10-05 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
CA3024817A1 (en) * 2011-08-26 2013-03-07 Meiji Seika Pharma Co., Ltd. Method for producing pest control agent
EP2760870B1 (en) 2011-09-27 2016-05-04 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN102702223A (zh) * 2012-05-28 2012-10-03 盛世泰科生物医药技术(苏州)有限公司 一种2-溴-4-氯噻吩并[3,2-c]吡啶的制备方法
CN104349771A (zh) 2012-06-06 2015-02-11 诺华股份有限公司 用于治疗肿瘤疾病的17α-羟化酶(C17,20-裂解酶)抑制剂和特定PI-3K抑制剂的组合
CA2902335C (en) 2013-03-14 2021-09-14 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
TW201534586A (zh) * 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
JP2016526538A (ja) 2013-06-20 2016-09-05 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺ダニ剤及び殺虫剤としてのアリールスルフィド誘導体及びアリールスルホキシド誘導体
EP3718544A1 (en) * 2013-10-01 2020-10-07 Novartis AG Combination
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
MY187246A (en) 2014-03-14 2021-09-14 Novartis Ag Antibody molecules to lag-3 and uses thereof
AU2015314772B2 (en) 2014-09-12 2020-02-27 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
US9783527B2 (en) * 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MA40035A (fr) 2014-10-14 2016-04-21 Dana Farber Cancer Inst Inc Molécules d'anticorps de pd-l1 et leurs utilisations
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
SG11201800445PA (en) 2015-07-17 2018-02-27 Fujifilm Corp Nitrogen-containing heterocyclic compound
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
HRP20220436T1 (hr) 2015-11-03 2022-05-27 Janssen Biotech, Inc. Protutijela koja se specifično vežu na pd-1 i njihove uporabe
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CA3026564A1 (en) * 2016-06-06 2017-12-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Proteasome inhibitors
US11345724B2 (en) 2016-06-06 2022-05-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Proteasome inhibitors
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
AU2017350690A1 (en) 2016-10-24 2019-06-13 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
CN110430878A (zh) 2016-12-27 2019-11-08 富士胶片株式会社 抗肿瘤剂及溴结构域抑制剂
CN108264509B (zh) * 2016-12-30 2021-05-04 复旦大学 取代的苯并噻吩并[2，3-c]四氢吡啶衍生物及其制备方法和用途
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
AU2019230014A1 (en) 2018-03-05 2020-09-17 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
EA202092253A1 (ru) 2018-03-22 2021-01-14 Ауриген Дискавери Текнолоджиз Лимитед Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
BR112022001508A2 (pt) * 2019-08-08 2022-07-12 Laekna Ltd Método de tratamento de câncer
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202321210A (zh) * 2021-07-22 2023-06-01 瑞士商諾華公司 用於治療冠狀病毒相關疾病之化合物及組成物
CN115304591B (zh) * 2022-07-08 2024-10-01 广州中医药大学(广州中医药研究院) 一种桥环甾体合成酶抑制剂及其制备方法和应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL39283A (en) * 1971-05-03 1976-01-30 Ciba Geigy Ag Substituted 2-oxo or thioxo-3-(5-nitro-imidazol-2-yl)-tetrahydroimidazoles and their manufacture
CH590266A5 (pt) * 1972-10-04 1977-07-29 Ciba Geigy Ag
DE2701794A1 (de) * 1976-01-21 1977-07-28 Ciba Geigy Ag Oxigenierte n-aryl-diazacyclen
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
AU606677B2 (en) 1987-04-22 1991-02-14 Merrell Dow Pharmaceuticals Inc. 17 beta -(cyclopropylimino) androst-5-EN-3 beta- Ol and related compounds useful as C17-20 lyase inhibitors
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
WO1992015404A1 (en) 1991-03-01 1992-09-17 S.L. Electrostatic Technology, Inc. Powder coating method for producing circuit board laminae and the like
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5457102A (en) 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
KR100235135B1 (ko) 1992-03-31 2000-01-15 말콤 카터 암치료에 유용한 17-치환된 스테로이드
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5270329A (en) * 1992-12-10 1993-12-14 Eli Lilly And Company Antitumor compositions and methods of treatment
DE4332168A1 (de) * 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
JP3916092B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬
KR960704852A (ko) 1993-09-30 1996-10-09 오노다 마사요시 아졸 유도체 및 이의 약제학적 조성물 (Azole derivative and pharmaceutical composition thereof)
AU676088B2 (en) 1993-09-30 1997-02-27 British Technology Group Limited Synthesis of 17-(3-pyridyl) steroids
WO1996014090A1 (en) 1994-11-07 1996-05-17 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
JPH08176111A (ja) * 1994-12-20 1996-07-09 Kyorin Pharmaceut Co Ltd Ｎ，ｎ′−ジ置換エチレンジアミン誘導体及びそれらを用いたｎ，ｎ′−ジ置換イミダゾリジノン誘導体の製造方法
EP3103799B1 (en) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
WO1997000257A1 (fr) 1995-06-14 1997-01-03 Yamanouchi Pharmaceutical Co., Ltd. Derives d'imidazole fusionnes et composition medicinale les contenant
NZ312665A (en) 1995-07-06 1999-08-30 Novartis Ag Rrolopyrimidines(7h-pyrrolo[2,3-d]pyrimidine and preparation of these
WO1997008150A1 (en) 1995-08-22 1997-03-06 The Du Pont Merck Pharmaceutical Company Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US6150352A (en) * 1996-05-20 2000-11-21 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE938597T1 (de) 1996-09-06 2000-03-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
AU753546B2 (en) 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ATE264304T1 (de) 1997-10-02 2004-04-15 Daiichi Seiyaku Co Dihydronaphthalinderivate und verfahren zur herstellung derselben
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
WO1999043653A1 (en) 1998-02-25 1999-09-02 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
US6573289B1 (en) 1998-04-23 2003-06-03 Takeda Chemical Industries, Ltd. Naphthalene derivatives, their production and use
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
KR100716272B1 (ko) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
ATE329596T1 (de) 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
AU3294701A (en) 2000-01-28 2001-08-07 Bristol-Myers Squibb Company Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
JP2002302488A (ja) * 2000-03-30 2002-10-18 Takeda Chem Ind Ltd 置換１，３−チアゾール化合物、その製造法および用途
NO312876B1 (no) * 2000-07-21 2002-07-15 Balans Man As Regulerbar stol
WO2002020493A2 (en) 2000-09-06 2002-03-14 Chugai Seiyaku Kabushiki Kaisha A traceless solid-phase synthesis of 2-imidazolones
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US20040198773A1 (en) 2001-09-26 2004-10-07 Barry Hart Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
GB0200283D0 (en) * 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
AU2003256755A1 (en) * 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
KR20050057392A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
WO2006078698A1 (en) 2005-01-19 2006-07-27 Cengent Therapeutics, Inc. 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases
SI2206719T1 (sl) 2005-03-02 2015-03-31 University Of Maryland, Baltimore Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
AR060050A1 (es) 2006-03-21 2008-05-21 Epix Delaware Inc Compuestos moduladores del receptor de s1p y uso de los mismos
EP2063963A2 (en) 2006-08-25 2009-06-03 Cougar Biotechnology, Inc. Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent
WO2008044700A1 (fr) * 2006-10-11 2008-04-17 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
WO2008094556A2 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
WO2008154382A1 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
CN101084881B (zh) 2007-06-23 2012-08-29 淮北辉克药业有限公司 靶向速释泡腾制剂及其制备方法
WO2009078992A1 (en) * 2007-12-17 2009-06-25 Amgen Inc. Linear tricyclic compounds as p38 kinase inhibitors
CA2712897A1 (en) * 2008-01-30 2009-08-06 Pharmacopeia, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
PE20091972A1 (es) * 2008-05-19 2010-01-15 Schering Corp Compuestos heterociclicos como inhibidores del factor ixa
MX2011000175A (es) 2008-06-25 2011-06-27 Envivo Pharmaceuticals Inc Compuestos heterociclicos 1,2-di-substituidos.
NZ589962A (en) 2008-06-27 2012-12-21 Novartis Ag Inhibitors of stearoyl-CoA desaturase and uses thereof
WO2010045303A2 (en) 2008-10-16 2010-04-22 Schering Corporation Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
WO2010099518A2 (en) * 2009-02-27 2010-09-02 Thesis Chemistry, Llc Method for manufacture of 2-oxoimidazolidines
US8791094B2 (en) 2009-08-07 2014-07-29 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
JP5956928B2 (ja) 2009-11-13 2016-07-27 トーカイ ファーマシューティカルズ，インク． 哺乳類のステロイドの代謝物質
WO2011088160A2 (en) 2010-01-15 2011-07-21 Biomarin Pharmaceutical Inc. Novel cyp17 inhibitors
GB201002563D0 (en) 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds

Also Published As

Publication number Publication date
PL2445903T3 (pl) 2014-08-29
TW201103915A (en) 2011-02-01
WO2010149755A1 (en) 2010-12-29
JO2892B1 (en) 2015-09-15
US20140228394A1 (en) 2014-08-14
EA021011B1 (ru) 2015-03-31
CA2765983A1 (en) 2010-12-29
GEP20156250B (en) 2015-02-25
ECSP12011625A (es) 2012-02-29
PE20121048A1 (es) 2012-08-25
HK1164876A1 (en) 2012-09-28
ES2475945T3 (es) 2014-07-11
HRP20140593T1 (hr) 2014-08-01
MA33451B1 (fr) 2012-07-03
RS53384B (en) 2014-10-31
SMT201400091B (it) 2014-09-08
IL216741A0 (en) 2012-02-29
HN2011003371A (es) 2015-08-10
CY1115426T1 (el) 2017-01-04
CN102803250A (zh) 2012-11-28
US20100331326A1 (en) 2010-12-30
MX2011013771A (es) 2012-02-22
BRPI1015568A2 (pt) 2016-08-16
AR078228A1 (es) 2011-10-26
KR101360725B1 (ko) 2014-02-07
SI2445903T1 (sl) 2014-07-31
CU24039B1 (es) 2014-11-27
UA105794C2 (uk) 2014-06-25
CR20110684A (es) 2012-02-15
CA2765983C (en) 2017-11-14
PT2445903E (pt) 2014-07-08
AU2010264698B2 (en) 2012-10-18
US8263635B2 (en) 2012-09-11
AU2010264698C1 (en) 2013-05-16
TN2011000611A1 (en) 2013-05-24
NI201100223A (es) 2012-08-03
AU2010264698A1 (en) 2011-12-08
ME01886B (me) 2014-12-20
IL216741A (en) 2015-08-31
JP5456891B2 (ja) 2014-04-02
BRPI1015568B1 (pt) 2020-11-17
TWI492942B (zh) 2015-07-21
JP2012530763A (ja) 2012-12-06
DK2445903T3 (da) 2014-06-23
CU20110235A7 (es) 2012-06-21
MY155570A (en) 2015-10-30
NZ596488A (en) 2012-11-30
SG176105A1 (en) 2011-12-29
ZA201108373B (en) 2012-07-25
EP2445903A1 (en) 2012-05-02
EA201200049A1 (ru) 2012-08-30
USRE45173E1 (en) 2014-09-30
KR20120035195A (ko) 2012-04-13
CO6480927A2 (es) 2012-07-16
CN102803250B (zh) 2014-04-16
CL2011003266A1 (es) 2012-07-06
UY32730A (es) 2011-01-31
DOP2011000399A (es) 2012-01-15
EP2445903B1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
BRPI1015568B8 (pt) derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CY1124117T1 (el) Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων
BRPI0915084B8 (pt) composto, e, composição farmacêutica
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
UY31952A (es) 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
SV2010003491A (es) 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
BR112012008518A2 (pt) derivado heterocíclico, e, composição farmacêutica
UY31189A1 (es) Compuestos heterocíclicos
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
ATE557015T1 (de) 3,4-diarylpyrazole als proteinkinaseinhibitoren
BR112015021549A2 (pt) inibidores de piridina cinase cdk9
DOP2011000218A (es) Derivados de sulfonamida
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
BR112012000763B8 (pt) compostos derivados de piridin-4-il, composição farmacêutica, e, usos de um composto
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
EA201390198A1 (ru) Гетероциклическое соединение
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
MX2011009847A (es) Agentes antihelminticos y su uso.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF